GlassScriptPhysician profile
Toby Paulson
NPI 1235264169
$19,492.16
in general payments reported to CMS, 2019-2025
33 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $648 · 2021: $1,004 · 2022: $879 · 2023: $896 · 2024: $3,817 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $2,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $2,632.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13,686.61 | 2019-2025 | Lifevest |
| Pfizer INC. | $813.53 | 2019-2025 | |
| Abbott Laboratories | $651.53 | 2020-2025 | Jot Dx |
| Novartis Pharmaceuticals Corporation | $598.14 | 2019-2025 | |
| Amgen INC. | $551.32 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $403.01 | 2019-2025 | General - Therapies |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.35 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $325.94 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $298.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $262.67 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $246.53 | 2019-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $178.29 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $148.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $120.54 | 2023-2025 | Verquvo |
| Amarin Pharma, INC. | $102.51 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.93 | 2019 | |
| Esperion Therapeutics, INC. | $79.89 | 2020-2024 | Nexletol |
| Edwards Lifesciences Corporation | $75.89 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $52.66 | 2024-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $51.01 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $48.06 | 2023-2024 | Inpefa |
| Gilead Sciences, INC. | $46.89 | 2019 | |
| United Therapeutics Corporation | $45.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.30 | 2020-2022 | |
| Scpharmaceuticals INC. | $33.68 | 2025 | |
| Teleflex LLC | $32.80 | 2023-2024 | Turnpike, Supercross |
| Cvrx, INC. | $29.57 | 2025 | Barostim Neo System |
| Inari Medical, INC. | $25.37 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $22.50 | 2021 | |
| Biotronik INC. | $18.45 | 2022 | |
| Genzyme Corporation | $16.05 | 2022 | |
| Cmp Pharma, INC. | $15.30 | 2022 | |
| Inspire Medical Systems, INC. | $14.03 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Paulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.